vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
CALLAN JMB INC. is the larger business by last-quarter revenue ($1.2M vs $906.0K, roughly 1.3× Mind Medicine (MindMed) Inc.). CALLAN JMB INC. runs the higher net margin — -223.8% vs -2634.0%, a 2410.2% gap on every dollar of revenue.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
CJMB vs DFTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $906.0K |
| Net Profit | $-2.6M | $-23.9M |
| Gross Margin | 30.3% | — |
| Operating Margin | -216.6% | -2450.8% |
| Net Margin | -223.8% | -2634.0% |
| Revenue YoY | — | -16.1% |
| Net Profit YoY | — | -386.7% |
| EPS (diluted) | $-0.58 | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $1.7M | — | ||
| Q1 25 | $1.4M | — | ||
| Q4 23 | — | $906.0K | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | — | $1.3M | ||
| Q1 23 | — | $1.3M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.7M | — | ||
| Q2 25 | $-1.4M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 23 | — | $-23.9M | ||
| Q3 23 | — | $-17.9M | ||
| Q2 23 | — | $-29.1M | ||
| Q1 23 | — | $-24.8M |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 38.6% | — | ||
| Q1 25 | 42.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | -216.6% | — | ||
| Q3 25 | -129.9% | — | ||
| Q2 25 | -84.2% | — | ||
| Q1 25 | -85.4% | — | ||
| Q4 23 | — | -2450.8% | ||
| Q3 23 | — | -1858.6% | ||
| Q2 23 | — | -2226.1% | ||
| Q1 23 | — | -1624.8% |
| Q4 25 | -223.8% | — | ||
| Q3 25 | -188.8% | — | ||
| Q2 25 | -83.9% | — | ||
| Q1 25 | -85.6% | — | ||
| Q4 23 | — | -2634.0% | ||
| Q3 23 | — | -1541.1% | ||
| Q2 23 | — | -2222.0% | ||
| Q1 23 | — | -1932.6% |
| Q4 25 | $-0.58 | — | ||
| Q3 25 | $-0.61 | — | ||
| Q2 25 | $-0.31 | — | ||
| Q1 25 | $-0.32 | — | ||
| Q4 23 | — | $-0.58 | ||
| Q3 23 | — | $-0.45 | ||
| Q2 23 | — | $-0.76 | ||
| Q1 23 | — | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $78.1M |
| Total Assets | $5.8M | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $5.2M | — | ||
| Q4 23 | — | $99.7M | ||
| Q3 23 | — | $117.7M | ||
| Q2 23 | — | $116.9M | ||
| Q1 23 | — | $129.4M |
| Q4 25 | $2.3M | — | ||
| Q3 25 | $4.2M | — | ||
| Q2 25 | $5.8M | — | ||
| Q1 25 | $6.8M | — | ||
| Q4 23 | — | $78.1M | ||
| Q3 23 | — | $96.0M | ||
| Q2 23 | — | $106.0M | ||
| Q1 23 | — | $130.3M |
| Q4 25 | $5.8M | — | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $9.0M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 23 | — | $124.5M | ||
| Q3 23 | — | $141.6M | ||
| Q2 23 | — | $142.1M | ||
| Q1 23 | — | $155.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-20.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | — | ||
| Q3 25 | $-1.8M | — | ||
| Q2 25 | $-563.3K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 23 | — | $-20.6M | ||
| Q3 23 | — | $-16.6M | ||
| Q2 23 | — | $-13.8M | ||
| Q1 23 | — | $-13.3M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-995.8K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -133.5% | — | ||
| Q2 25 | -59.8% | — | ||
| Q1 25 | -108.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
DFTX
Segment breakdown not available.
